A multidisciplinary training program in prostate cancer

前列腺癌是美国男性癌症相关死亡的第二大原因， 预计2018年约有29,000人死亡。它最初对雄激素消融有反应，但最终 进展到更晚期的疾病状态，称为转移性去势抵抗前列腺癌。那里 目前有六种FDA批准的治疗mCRPC的方法，每种方法都能将生存期延长约2-4 月份。然而，每年有近16.5万名男性确诊，有100多万人患有这种疾病 在美国，管理生活质量和疾病进展的风险是需要关注的未得到满足的关切。这个 塞达斯-西奈医学中心的Samuel Oschin综合癌症研究所(SOCCI)治疗的比例最高 西海岸的癌症病人数量。研究成果的转化有助于更有效地 诊断、治疗和预防多种形式的癌症的方法是SOCCI的核心使命。14名教职员工 (初级和二级)致力于前列腺癌博士、医学博士和医学博士/博士的培训1)生物学，2)临床 试验，以及3)卫生服务研究有助于机构对高水平癌症患者的承诺 关心。作为证据，88%的实习生(博士和医学博士)这使得该计划在过去五年里一直在做 学术界或制药业的研究。将实验室科学转化为临床试验和 来自临床观察的实验假说的发展来自于与 临床医生/外科医生-科学家。所有受训人员将参与负责任的研究、赠款撰写和 传播讲习班、生物统计单元以及定期会议和研讨会。平均而言， 4.6前列腺癌培训每年提供新的培训助学金(TGE)博士后研究员 项目教师；我们正在为1-2年级的一名新博士后实习生和两名新的博士后实习生申请资金支持 3-5年级的研究员，培养合作前列腺癌研究的领导者，以促进更好的患者护理。 南加州的人口以及与代表不足的少数族裔研究生项目的互动 全国各地都是申请者群体的一部分。在过去的五年里，25%的TGE博士后 参加该计划的候选人是代表不足的少数族裔。这一新的T32应用程序计划严格 研究培训、个性化的职业发展和密切的导师关系，以满足年轻人的需求 调查人员和癌症患者的护理。

Prostate cancer is the second leading cause of cancer related death in men in the United States, with approximately 29,000 deaths projected for 2018. It is initially responsive to androgen-ablation, but eventually progresses to a more advanced disease state known as metastatic castration-resistant prostate cancer. There are currently six FDA-approved therapies for mCRPC each of which extends survival by approximately 2-4 months. However, with nearly 165,000 men diagnosed yearly and over a million living with the disease in the US, managing quality of life and risk of progression of the disease are unmet concerns that need attention. The Samuel Oschin Comprehensive Cancer Institute (SOCCI) at Cedars-Sinai Medical Center treat the highest volume of cancer patient on the west coast. The translation of research discoveries contributing to more effective ways to diagnose, treat, and prevent many forms of cancer is a core mission of the SOCCI. The 14 faculty (primary and secondary) dedicated to training PhD, MD, and MD/PhD in prostate cancer 1) biology, 2) clinical trial, and 3) health services research contribute to the institutional commitment to high level of cancer patient care. As evidence, 88% of the trainees (Ph.D. and M.D.) that left the program in the past five years are doing research in academics or pharmaceutical industry. The translation of the bench science to clinical trials and development of experimental hypothesizes from clinical observations is derived from collaborations with clinician/surgeon-scientists. All trainees will participate in responsible conduct in research, grant writing and communication workshops, and biostatistics modules along with regular conferences and seminars. On average, 4.6 new training grant eligible (TGE) postdoctoral fellows are available yearly to the Prostate Cancer Training Program faculty; we are requesting funding support for one new postdoctoral trainee in years 1-2 and two new fellows in years 3-5 to develop leaders in collaborative prostate cancer research to promote better patient care. The population of southern California and interactions with underrepresented minority graduate programs throughout the country are part of the applicant pool. In the past five years, 25% of the TGE postdoctoral candidates that joined the program were underrepresented minority. This new T32 application plans for rigorous research training, personalized career development, and close mentorship to address the needs of young investigators and cancer patient care.